CNS Pharmaceuticals Financials
This page shows CNS Pharmaceuticals (CNSP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
CNS Pharmaceuticals passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, CNS Pharmaceuticals generates $1.15 in operating cash flow (-$17.1M OCF vs -$14.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
CNS Pharmaceuticals earns $-924.4 in operating income for every $1 of interest expense (-$14.9M vs $16K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
CNS Pharmaceuticals's EBITDA was -$14.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 21.0% from the prior year.
CNS Pharmaceuticals generated -$17.1M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 21.0% from the prior year.
CNS Pharmaceuticals reported -$14.9M in net income in fiscal year 2024. This represents an increase of 21.2% from the prior year.
CNS Pharmaceuticals earned $-38.87 per diluted share (EPS) in fiscal year 2024. This represents an increase of 99.7% from the prior year.
CNS Pharmaceuticals held $6.5M in cash against $0 in long-term debt as of fiscal year 2024.
CNS Pharmaceuticals had 117,796 shares outstanding in fiscal year 2024. This represents an increase of 4638.4% from the prior year.
CNS Pharmaceuticals invested $9.3M in research and development in fiscal year 2024. This represents a decrease of 34.1% from the prior year.
CNS Pharmaceuticals invested $4K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 7.4% from the prior year.
CNSP Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.2M-48.2% | $4.2M | N/A | $3.4M | N/A | $2.2M | N/A | $2.6M |
| SG&A Expenses | $1.1M-23.7% | $1.4M | N/A | $1.1M | N/A | $1.2M | N/A | $1.2M |
| Operating Income | -$3.3M+42.2% | -$5.6M | N/A | -$4.5M | N/A | -$3.4M | N/A | -$3.8M |
| Interest Expense | $2K-6.3% | $2K | N/A | $2K | N/A | $538 | N/A | $947 |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$3.2M+42.6% | -$5.6M | N/A | -$4.5M | N/A | -$3.4M | N/A | -$3.8M |
| EPS (Diluted) | $-5.76 | $-153.20 | N/A | $-54.14 | N/A | $-2.56 | N/A | $-0.14 |
CNSP Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.9M+36.4% | $8.7M+411.6% | $1.7M-26.9% | $2.3M-82.2% | $13.1M+35.4% | $9.6M+10.1% | $8.8M-23.9% | $11.5M |
| Current Assets | $11.4M+31.6% | $8.7M+444.2% | $1.6M-22.8% | $2.1M-83.6% | $12.6M+44.4% | $8.7M+16.4% | $7.5M-33.0% | $11.2M |
| Cash & Equivalents | $9.9M+52.7% | $6.5M+1077.5% | $549K-39.7% | $910K-91.0% | $10.1M+43.1% | $7.0M+40.4% | $5.0M-39.9% | $8.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.0M-22.4% | $2.5M-58.8% | $6.1M+50.7% | $4.1M-17.3% | $4.9M+295.4% | $1.2M-52.0% | $2.6M+7.8% | $2.4M |
| Current Liabilities | $2.0M-22.4% | $2.5M-58.8% | $6.1M+50.7% | $4.1M-17.3% | $4.9M+295.4% | $1.2M-52.0% | $2.6M+7.8% | $2.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $9.9M+60.4% | $6.2M+239.4% | -$4.4M-154.6% | -$1.7M-121.4% | $8.1M+7.5% | $7.6M+22.8% | $6.2M-32.3% | $9.1M |
| Retained Earnings | -$94.3M-11.7% | -$84.4M-21.4% | -$69.6M-8.4% | -$64.2M-26.6% | -$50.7M-13.3% | -$44.8M-26.3% | -$35.4M-10.1% | -$32.2M |
CNSP Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.2M+60.3% | -$5.5M-115.7% | -$2.5M+24.9% | -$3.4M-46.5% | -$2.3M-27.2% | -$1.8M+44.0% | -$3.2M-62.2% | -$2.0M |
| Capital Expenditures | N/A | $4K+94.2% | $2K+23.7% | $2K+174500.0% | -$1-100.1% | $2K-27.1% | $2K | $0 |
| Free Cash Flow | N/A | -$5.5M-115.7% | -$2.5M+24.9% | -$3.4M-46.5% | -$2.3M-27.1% | -$1.8M+44.0% | -$3.2M-62.3% | -$2.0M |
| Investing Cash Flow | N/A | -$4K-94.2% | -$2K-23.7% | -$2K-174500.0% | $1+100.1% | -$2K+27.1% | -$2K | $0 |
| Financing Cash Flow | -$92K-101.8% | $5.0M+127.9% | $2.2M+25952.0% | $8K-99.8% | $5.3M+4653.0% | -$117K-41.4% | -$83K-102.4% | $3.4M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CNSP Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -27.1%+48.5pp | -75.7% | N/A | -194.3% | N/A | -35.5% | N/A | -33.1% |
| Current Ratio | 5.81+2.4 | 3.43+3.2 | 0.26-0.2 | 0.51-2.0 | 2.55-4.4 | 6.99+4.1 | 2.88-1.8 | 4.63 |
| Debt-to-Equity | 0.20-0.2 | 0.41+1.8 | -1.38+1.0 | -2.34-2.9 | 0.60+0.4 | 0.16-0.3 | 0.42+0.2 | 0.26 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is CNS Pharmaceuticals profitable?
No, CNS Pharmaceuticals (CNSP) reported a net income of -$14.9M in fiscal year 2024.
What is CNS Pharmaceuticals's earnings per share (EPS)?
CNS Pharmaceuticals (CNSP) reported diluted earnings per share of $-38.87 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is CNS Pharmaceuticals's EBITDA?
CNS Pharmaceuticals (CNSP) had EBITDA of -$14.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is CNS Pharmaceuticals's free cash flow?
CNS Pharmaceuticals (CNSP) generated -$17.1M in free cash flow during fiscal year 2024. This represents a -21.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is CNS Pharmaceuticals's operating cash flow?
CNS Pharmaceuticals (CNSP) generated -$17.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are CNS Pharmaceuticals's total assets?
CNS Pharmaceuticals (CNSP) had $8.7M in total assets as of fiscal year 2024, including both current and long-term assets.
What are CNS Pharmaceuticals's capital expenditures?
CNS Pharmaceuticals (CNSP) invested $4K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does CNS Pharmaceuticals spend on research and development?
CNS Pharmaceuticals (CNSP) invested $9.3M in research and development during fiscal year 2024.
How many shares does CNS Pharmaceuticals have outstanding?
CNS Pharmaceuticals (CNSP) had 117,796 shares outstanding as of fiscal year 2024.
What is CNS Pharmaceuticals's current ratio?
CNS Pharmaceuticals (CNSP) had a current ratio of 3.43 as of fiscal year 2024, which is generally considered healthy.
What is CNS Pharmaceuticals's debt-to-equity ratio?
CNS Pharmaceuticals (CNSP) had a debt-to-equity ratio of 0.41 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is CNS Pharmaceuticals's return on assets (ROA)?
CNS Pharmaceuticals (CNSP) had a return on assets of -170.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is CNS Pharmaceuticals's cash runway?
Based on fiscal year 2024 data, CNS Pharmaceuticals (CNSP) had $6.5M in cash against an annual operating cash burn of $17.1M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is CNS Pharmaceuticals's Piotroski F-Score?
CNS Pharmaceuticals (CNSP) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are CNS Pharmaceuticals's earnings high quality?
CNS Pharmaceuticals (CNSP) has an earnings quality ratio of 1.15x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can CNS Pharmaceuticals cover its interest payments?
CNS Pharmaceuticals (CNSP) has an interest coverage ratio of -924.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.